OCN201INT (TIC10 INT) glioma tumor

Product Name：ONC201INT
MF：C11H15N3

MW：189.26
CAS：38941-29-6

Biological activity：
TIC10 (ONC201) inhibits Akt and ERK activity, induces TNF related pyroptosis in chemobook inducing ligand (TRAIL) through FoxO3a, exhibits superior drug resistance, can penetrate the blood-brain barrier, has super strong stability, and improved pharmacokinetic performance

                                                   ------------------- Company Profile ------------------

Tianyuan Pharmaceutical Co., Ltd. is devoted to researching, manufacturing and marketing medical raw materials. The company has established a multi-functional R&D center in Shenzhen Zhongcheng Biomedical Industrial Park, which has a group of innovativedrugs and generic drugs technicians and 60 foreign trade professionals.

Tianyuan pharmaceutical company has built 500 square meters of pilot laboratories, equipped with two sets of 50L glass reactor, four sets of 100L double reactor, six sets of 50L rotary evaporator and matching heating and cooling equipment, to complete the 10kg Pilot complex experiments in complex compounds, a steady cooperation of the amplification plant, from 100kg to the tonnage of the enlarged production.

Tianyuan medicine has been highly recognized by many well-known enterprises in the industry and has become their main supplier with high-quality products, honest and pragmatic attitude and good customer service. Tianyuan Medicine is dedicated to provide customers both at home and abroad with advanced technology and reasonable price , Quality products and professional technical services.